Which Vemlidy IMD among the 5 will rise to the top?

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.03.20 15:55:11

가나다라 0

3 drugs have already been released with reimb...reimb for the other 2 drugs are also in progress

Competition between the 4 companies that develop and supply the drugs vs 4 companies that sell the drugs upon consignment gain attention

Although failing to receive reimbursement in advance, many Vemlidy IMDs are awaiting entry into the Korean market. All the drugs are incrementally modified drugs that were developed with different salt formations.

According to industry sources on the 20th, 5 more companies are waiting to enter the market with Vemlidy latecomers. These companies follow the earlier entrants, such as Dong-A ST, which received reimbursement approval in January, and Chong Kun Dang and Daewoong Pharmaceuticals, which received reimbursement approvals in February.

Vemlidy (tenofovir ala fenamide) is an upgraded version of Gilead Science’s previous chronic hepatitis B treatment, ‘Viread (tenofovir).’ Vemlidy h

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)